The land of the maple leaf has done what the land of the free cannot: produce a generic version of Ozempic, the diabetes drug turned weight-loss wonder that has driven Americans to desperate measures. While patients in the United States pay hundreds of dollars monthly for the brand-name drug, Canadians can now access a generic version at a fraction of the cost. This is not a story of Canadian exceptionalism but of American regulatory failure.
To understand the disparity, one must look at the patent system. In the United States, pharmaceutical companies employ a strategy known as 'evergreening': making minor modifications to drugs to extend patent life, often through secondary patents covering formulations, dosages, or delivery methods. Ozempic's maker, Novo Nordisk, has used this tactic aggressively, keeping generic competition at bay until at least 2032 in the US. In Canada, patent laws are stricter. The Canadian Patent Act requires a higher standard of invention, and secondary patents are less likely to be granted. Consequently, generic manufacturers have been able to bring a version of semaglutide to market earlier.
This is where the fall of Rome meets the Victorian era. The United States, once the bastion of free market innovation, now resembles a decadent empire where monopolies thrive under the guise of intellectual property. The patent system, originally designed to encourage innovation, has become a tool for rent-seeking. Meanwhile, Canada, like the prudent Britons of old, has maintained a more balanced approach, protecting genuine innovation while curbing monopolistic abuse.
But there is a deeper cultural dimension. Americans, with their frontier mentality, still cling to the myth of the lone inventor and the unassailable right of property. They tolerate high drug prices because they believe in a system where anyone can strike it rich. Canadians, by contrast, have a more collectivist ethos, dating back to the Loyalist exodus after the American Revolution. They are more willing to regulate markets for the common good.
This difference has real consequences. In the US, patients are rationing their Ozempic, taking lower doses or skipping weeks, because of cost. Diabetic complications will rise. Meanwhile, Canadians with type 2 diabetes will have reliable access to a drug that, let us remember, was discovered in part by a Canadian researcher at the University of Toronto. The irony is rich.
Yet the American system is not immutable. The Inflation Reduction Act of 2022 includes provisions for Medicare price negotiation, starting in 2026. But that only applies to a limited set of drugs. True reform would require breaking the stranglehold of Big Pharma on Congress, a task Herculean in scale.
In the meantime, a stream of Americans will continue to cross the border for cheaper drugs, or buy Canadian generics online at their own risk. The US will remain a place where innovation is rewarded but access is denied, a contradiction that will eventually tear at the fabric of society. Canada, meanwhile, will quietly enjoy its victory in a war of attrition against pharma greed.
We should not celebrate too loudly. Canadian drug prices, while lower than US prices, are still higher than those in Europe. The system is not perfect. But it is a reminder that the pursuit of profit need not be absolute. As Gibbon might have noted, the decline of an empire often begins with the abandonment of common sense in favour of sacred cows. The American patent cow is due for slaughter.
